Literature DB >> 11380404

Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia.

M R Ricciardi1, M T Petrucci, C Gregorj, C Ariola, R M Lemoli, M Fogli, F R Mauro, R Cerretti, R Foà, F Mandelli, A Tafuri.   

Abstract

The role of apoptosis and cell kinetics in the mechanisms of disease progression of chronic lymphocytic leukaemia (CLL) is still unclear. In the present study, we investigated the susceptibility of leukaemic cells taken from 75 CLL patients with either stable (STD) or progressive disease (PRD) to enter apoptosis. Particular attention was paid to the relationship between cell cycle status and autologous serum (AS). The susceptibility to enter apoptosis was significantly greater in STD than in PRD, both in standard medium (mean = 23.62% +/- 14.7 versus 14.23% +/- 7.2; P = 0.02) and in the presence of AS (mean = 23.03% +/- 17.9 versus 11.27% +/- 7.6; P = 0.01). Furthermore, cell kinetics studies revealed a higher quiescence in PRD than in STD cases, both in terms of a lower RNA content (P = 0.04) and of higher expression of the negative cell cycle regulator p27kip1 (P = 0.03). These kinetic differences were confirmed by short-term in vitro culture both in fetal calf serum and in AS. The results of this study indicate that CLL cells from PRD cases are characterized by a higher degree quiescence and much lower susceptibility to apoptosis when compared with STD ones. In this context, AS does not appear to play a specific role. The association between these kinetic characteristics and disease progression in CLL prompts further studies to establish whether higher quiescence may be responsible for the decreased susceptibility of PRD cells to enter apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380404     DOI: 10.1046/j.1365-2141.2001.02708.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Authors:  Germano Mariano; Maria Rosaria Ricciardi; Daniela Trisciuoglio; Michele Zampieri; Fabio Ciccarone; Tiziana Guastafierro; Roberta Calabrese; Elisabetta Valentini; Agostino Tafuri; Donatella Del Bufalo; Paola Caiafa; Anna Reale
Journal:  Oncotarget       Date:  2015-06-20

2.  Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite.

Authors:  M R Ricciardi; R Licchetta; S Mirabilii; M Scarpari; A Parroni; A A Fabbri; P Cescutti; M Reverberi; C Fanelli; A Tafuri
Journal:  Oxid Med Cell Longev       Date:  2017-11-15       Impact factor: 6.543

3.  Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Jan A Burger; Min Fu; Tejaswini Doifode; William G Wierda; Varsha Gandhi
Journal:  Neoplasia       Date:  2014-12       Impact factor: 5.715

4.  A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.

Authors:  T Sbarrato; E Horvilleur; T Pöyry; K Hill; L C Chaplin; R V Spriggs; M Stoneley; L Wilson; S Jayne; T Vulliamy; D Beck; I Dokal; M J S Dyer; A M Yeomans; G Packham; M Bushell; S D Wagner; A E Willis
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.